Chronic, recurrent Lymphocytic Leukemia Completed Phase 2 Trials for Rituximab (DB00073)
Also known as: Recurrent Chronic Lymphocytic Leukemia
| Indication | Status | Phase |
|---|---|---|
| DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia) | Completed | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00764517 | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | Treatment |